CA3037723A1 - Agents and methods for modulating the sensory impact of tobacco or herbal smoke - Google Patents
Agents and methods for modulating the sensory impact of tobacco or herbal smoke Download PDFInfo
- Publication number
- CA3037723A1 CA3037723A1 CA3037723A CA3037723A CA3037723A1 CA 3037723 A1 CA3037723 A1 CA 3037723A1 CA 3037723 A CA3037723 A CA 3037723A CA 3037723 A CA3037723 A CA 3037723A CA 3037723 A1 CA3037723 A1 CA 3037723A1
- Authority
- CA
- Canada
- Prior art keywords
- agent
- channel
- activates
- tobacco
- operable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000208125 Nicotiana Species 0.000 title claims abstract description 73
- 235000002637 Nicotiana tabacum Nutrition 0.000 title claims abstract description 73
- 239000000779 smoke Substances 0.000 title abstract description 24
- 230000001953 sensory effect Effects 0.000 title abstract description 22
- 238000000034 method Methods 0.000 title description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 72
- 108091006146 Channels Proteins 0.000 claims abstract description 42
- 230000035807 sensation Effects 0.000 claims abstract description 28
- CZNLTCTYLMYLHL-UHFFFAOYSA-N [6]-Paradol Chemical compound CCCCCCCC(=O)CCC1=CC=C(O)C(OC)=C1 CZNLTCTYLMYLHL-UHFFFAOYSA-N 0.000 claims abstract description 26
- 102000003566 TRPV1 Human genes 0.000 claims abstract description 21
- 102000003568 TRPV3 Human genes 0.000 claims abstract description 21
- 101150016206 Trpv1 gene Proteins 0.000 claims abstract description 21
- 101150043371 Trpv3 gene Proteins 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 244000062241 Kaempferia galanga Species 0.000 claims abstract description 15
- 235000013421 Kaempferia galanga Nutrition 0.000 claims abstract description 15
- 102000003610 TRPM8 Human genes 0.000 claims abstract description 13
- 101150111302 Trpm8 gene Proteins 0.000 claims abstract description 13
- 244000227206 Aframomum melegueta Species 0.000 claims abstract description 11
- 235000015752 Aframomum melegueta Nutrition 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 108010036769 TRPA1 Cation Channel Proteins 0.000 claims abstract description 6
- 102000012253 TRPA1 Cation Channel Human genes 0.000 claims abstract description 6
- 239000001857 aframomum melegueta rosc. k. schum. Substances 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims description 17
- 244000269722 Thea sinensis Species 0.000 claims description 10
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 9
- 230000035597 cooling sensation Effects 0.000 claims description 8
- 238000010792 warming Methods 0.000 claims description 8
- -1 Cool-actP Chemical compound 0.000 claims description 7
- LMXFTMYMHGYJEI-IWSPIJDZSA-N (1R,2R,5R)-2-(1-hydroxy-1-methylethyl)-5-methylcyclohexanol Chemical compound C[C@@H]1CC[C@@H](C(C)(C)O)[C@H](O)C1 LMXFTMYMHGYJEI-IWSPIJDZSA-N 0.000 claims description 6
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 6
- 241000723346 Cinnamomum camphora Species 0.000 claims description 6
- KRCZYMFUWVJCLI-UHFFFAOYSA-N Dihydrocarveol Chemical compound CC1CCC(C(C)=C)CC1O KRCZYMFUWVJCLI-UHFFFAOYSA-N 0.000 claims description 6
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims description 6
- 229930008380 camphor Natural products 0.000 claims description 6
- 229960000846 camphor Drugs 0.000 claims description 6
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 6
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 6
- 235000002566 Capsicum Nutrition 0.000 claims description 5
- 239000005844 Thymol Substances 0.000 claims description 5
- 229960000790 thymol Drugs 0.000 claims description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 244000203593 Piper nigrum Species 0.000 claims description 4
- 235000008184 Piper nigrum Nutrition 0.000 claims description 4
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 4
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 4
- 235000007746 carvacrol Nutrition 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 3
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 3
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 3
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 3
- RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 claims description 3
- 244000056139 Brassica cretica Species 0.000 claims description 3
- 235000003351 Brassica cretica Nutrition 0.000 claims description 3
- 235000003343 Brassica rupestris Nutrition 0.000 claims description 3
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 3
- VUNOFAIHSALQQH-UHFFFAOYSA-N Ethyl menthane carboxamide Chemical compound CCNC(=O)C1CC(C)CCC1C(C)C VUNOFAIHSALQQH-UHFFFAOYSA-N 0.000 claims description 3
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims description 3
- 239000005770 Eugenol Substances 0.000 claims description 3
- 239000005792 Geraniol Substances 0.000 claims description 3
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims description 3
- ZBJCYZPANVLBRK-UHFFFAOYSA-N Menthone 1,2-glyceryl ketal Chemical compound CC(C)C1CCC(C)CC11OC(CO)CO1 ZBJCYZPANVLBRK-UHFFFAOYSA-N 0.000 claims description 3
- BLILOGGUTRWFNI-UHFFFAOYSA-N Monomenthyl succinate Chemical compound CC(C)C1CCC(C)CC1OC(=O)CCC(O)=O BLILOGGUTRWFNI-UHFFFAOYSA-N 0.000 claims description 3
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 claims description 3
- 241000208134 Nicotiana rustica Species 0.000 claims description 3
- 239000006002 Pepper Substances 0.000 claims description 3
- 240000008474 Pimenta dioica Species 0.000 claims description 3
- 235000006990 Pimenta dioica Nutrition 0.000 claims description 3
- 235000016761 Piper aduncum Nutrition 0.000 claims description 3
- 235000017804 Piper guineense Nutrition 0.000 claims description 3
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 3
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 3
- 229940116229 borneol Drugs 0.000 claims description 3
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 3
- 229960005233 cineole Drugs 0.000 claims description 3
- 229930007024 dihydrocarveol Natural products 0.000 claims description 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 3
- 229960002217 eugenol Drugs 0.000 claims description 3
- 229940113087 geraniol Drugs 0.000 claims description 3
- WPFVBOQKRVRMJB-UHFFFAOYSA-N hydroxycitronellal Chemical compound O=CCC(C)CCCC(C)(C)O WPFVBOQKRVRMJB-UHFFFAOYSA-N 0.000 claims description 3
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 3
- 229930007744 linalool Natural products 0.000 claims description 3
- 235000010460 mustard Nutrition 0.000 claims description 3
- 239000000284 extract Substances 0.000 abstract description 25
- 230000000391 smoking effect Effects 0.000 abstract description 21
- 238000002485 combustion reaction Methods 0.000 abstract description 9
- 239000007921 spray Substances 0.000 abstract description 4
- 235000019504 cigarettes Nutrition 0.000 description 45
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 38
- 229960002715 nicotine Drugs 0.000 description 38
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 38
- 235000019615 sensations Nutrition 0.000 description 23
- 239000000470 constituent Substances 0.000 description 20
- 210000003800 pharynx Anatomy 0.000 description 15
- 235000019788 craving Nutrition 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000011514 reflex Effects 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000000723 chemosensory effect Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 235000019505 tobacco product Nutrition 0.000 description 7
- JAMQIUWGGBSIKZ-UHFFFAOYSA-N 1'-acetoxychavicol acetate Chemical compound CC(=O)OC(C=C)C1=CC=C(OC(C)=O)C=C1 JAMQIUWGGBSIKZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000001774 alpinia officinarum Substances 0.000 description 6
- 239000002826 coolant Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 6
- 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 6
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 5
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108010009685 Cholinergic Receptors Proteins 0.000 description 4
- 102000034337 acetylcholine receptors Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000018811 Aframomum Nutrition 0.000 description 3
- 241001127758 Aframomum Species 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 235000019618 chemesthesis Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 235000009733 malagueta Nutrition 0.000 description 3
- 244000035400 malagueta Species 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008786 sensory perception of smell Effects 0.000 description 3
- 210000002265 sensory receptor cell Anatomy 0.000 description 3
- 102000027509 sensory receptors Human genes 0.000 description 3
- 108091008691 sensory receptors Proteins 0.000 description 3
- 230000005586 smoking cessation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920001144 Hydroxy alpha sanshool Polymers 0.000 description 2
- LHFKHAVGGJJQFF-UEOYEZOQSA-N Hydroxy-alpha-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UEOYEZOQSA-N 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- 241000758706 Piperaceae Species 0.000 description 2
- 229940123223 TRPA1 agonist Drugs 0.000 description 2
- 240000002657 Thymus vulgaris Species 0.000 description 2
- 235000007303 Thymus vulgaris Nutrition 0.000 description 2
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 description 2
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000001932 glossopharyngeal nerve Anatomy 0.000 description 2
- LHFKHAVGGJJQFF-UHFFFAOYSA-N hydroxyl-alpha-sanshool Natural products CC=CC=CC=CCCC=CC(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 235000019613 sensory perceptions of taste Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035923 taste sensation Effects 0.000 description 2
- 239000001585 thymus vulgaris Substances 0.000 description 2
- 210000003901 trigeminal nerve Anatomy 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- OXZSUQJHKQOGOK-UHFFFAOYSA-N Carvacrol acetate Natural products CC(C)C1=CC=C(C)C(OC(C)=O)=C1 OXZSUQJHKQOGOK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 239000002714 Extracts of rosemary Substances 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- HVBACKJYWZTKCA-XSLBTUIJSA-N O1[C@]2(C)CC[C@@]1(C(C)C)C/C=C(C)/CC/C=C(C)/CC[C@@H]2OC(C)=O Chemical compound O1[C@]2(C)CC[C@@]1(C(C)C)C/C=C(C)/CC/C=C(C)/CC[C@@H]2OC(C)=O HVBACKJYWZTKCA-XSLBTUIJSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 244000195452 Wasabia japonica Species 0.000 description 1
- 235000000760 Wasabia japonica Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000016720 allyl isothiocyanate Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019306 extracts of rosemary Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- HVBACKJYWZTKCA-FSSWDIPSSA-N incensole acetate Natural products CC(C)[C@]12CC[C@](C)(O1)[C@@H](CCC(C)=CCCC(C)=CC2)OC(C)=O HVBACKJYWZTKCA-FSSWDIPSSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000003155 kinesthetic effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 230000003238 somatosensory effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WFMIUXMJJBBOGJ-UHFFFAOYSA-N thymol acetate Natural products CC(C)C1=CC=C(C)C=C1OC(C)=O WFMIUXMJJBBOGJ-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F47/00—Smokers' requisites not otherwise provided for
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
- A24B15/283—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/302—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by natural substances obtained from animals or plants
- A24B15/303—Plant extracts other than tobacco
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacture Of Tobacco Products (AREA)
Abstract
A device and composition that mimics the sensation of inhaling tobacco smoke includes a wrapper containing a tobacco substitute. The substitute is coated with a first extract containing an agent that activates a TRPA1 channel, which includes grains of paradise, galangal, or 6-paradol, and a second extract with an agent that activates at least one of TRPM8, TRPV3, or TRPV1 channels. The extracts are applied as a spray to coat the tobacco substitute, which is then dried. When heated below the combustion point, the device releases volatile compounds, simulating the sensory experience of smoking without burning the tobacco substitute.
Description
AGENTS AND METHODS FOR MODULATING THE SENSORY
IMPACT OF TOBACCO OR HERBAL SMOKE
BACKGROUND
[0001] Tobacco smoke is a causal risk factor for cancer (especially but not exclusively lung cancer), cardiovascular disease, and lung dysfunction, including chronic obstructive pulmonary disease (COPD). Despite the recognized and widely known hazards of tobacco smoke, the addictive properties of cigarettes and other tobacco products have been a barrier to smoking cessation or reduction. There are a number of proposed strategies for reducing the harm associated with smoking. One attempted strategy has been to produce cigarettes with low tar and nicotine delivery during smoking, intended to be below the threshold for establishment or maintenance of nicotine addiction. Such "light" cigarettes have had little impact on smoking-related illnesses, in part due to low consumer satisfaction, but also because smokers tend to compensate for low nicotine, tar, and flavor component delivery by increasing the number and volume of puffs per cigarette, to titrate nicotine delivery or airway sensations to a level that provides relief from acute tobacco craving symptoms.
Another attempted strategy has been to develop methods for nicotine delivery without combustion of tobacco, including "heat-not-burn" technology that seeks to release nicotine from the tobacco via volatilization or formation of an aerosol without many of the toxicants in combusted tobacco smoke, but which still delivers the highly addictive drug nicotine.
IMPACT OF TOBACCO OR HERBAL SMOKE
BACKGROUND
[0001] Tobacco smoke is a causal risk factor for cancer (especially but not exclusively lung cancer), cardiovascular disease, and lung dysfunction, including chronic obstructive pulmonary disease (COPD). Despite the recognized and widely known hazards of tobacco smoke, the addictive properties of cigarettes and other tobacco products have been a barrier to smoking cessation or reduction. There are a number of proposed strategies for reducing the harm associated with smoking. One attempted strategy has been to produce cigarettes with low tar and nicotine delivery during smoking, intended to be below the threshold for establishment or maintenance of nicotine addiction. Such "light" cigarettes have had little impact on smoking-related illnesses, in part due to low consumer satisfaction, but also because smokers tend to compensate for low nicotine, tar, and flavor component delivery by increasing the number and volume of puffs per cigarette, to titrate nicotine delivery or airway sensations to a level that provides relief from acute tobacco craving symptoms.
Another attempted strategy has been to develop methods for nicotine delivery without combustion of tobacco, including "heat-not-burn" technology that seeks to release nicotine from the tobacco via volatilization or formation of an aerosol without many of the toxicants in combusted tobacco smoke, but which still delivers the highly addictive drug nicotine.
[0002] Smoking remains one of the leading causes of preventable morbidity and mortality throughout the world. The World Health Organization estimates there are around 1.3 billion tobacco users world-wide, and notes that tobacco use causes nearly 6 million deaths per year, with an estimated 8 million deaths a year by 2030, should current trends continue. The Centers for Disease Control and Prevention has stated that smoking is the leading cause of preventable death in the U.S., where there are an estimated 540,000 premature deaths per year due to cigarette smoking, and the economic cost of smoking is estimated to exceed S300 billion per year. In addition to providing smokers with effective smoking cessation treatment options, new approaches are needed to substitute for the rewarding effects of smoking using less harmful alternatives.
[0003] While tobacco is the leading cause of preventable disease and death, nicotine is the fundamental cause of addiction among tobacco users. Even by removing harmful toxins and carcinogens from combusted tobacco smoke, nicotine is well known to have serious side effects across all systems of the body including cardiovascular, respiratory, renal and
4 reproductive systems. The US Surgeon General has concluded that nicotine is as addictive as cocaine or heroin and thus is one of the most addicting agents known.
Studies have consistently demonstrated the carcinogenic potential of nicotine. The US Food and Drug Administration (FDA) recently announced its intention to place nicotine at the center of its regulation of tobacco products, believing that reducing nicotine in tobacco products can significantly reduce tobacco-related disease and death. There is a growing acceptance that isolating nicotine use from smoking is only a partial solution and that finding safer alternatives to nicotine should be a priority.
BRIEF SUMMARY
[0004] In an example, a device includes a wrapper, tobacco disposed in the wrapper, and a first agent that activates a TRPA1 channel disposed in the wrapper.
Studies have consistently demonstrated the carcinogenic potential of nicotine. The US Food and Drug Administration (FDA) recently announced its intention to place nicotine at the center of its regulation of tobacco products, believing that reducing nicotine in tobacco products can significantly reduce tobacco-related disease and death. There is a growing acceptance that isolating nicotine use from smoking is only a partial solution and that finding safer alternatives to nicotine should be a priority.
BRIEF SUMMARY
[0004] In an example, a device includes a wrapper, tobacco disposed in the wrapper, and a first agent that activates a TRPA1 channel disposed in the wrapper.
[0005] The first agent may include at least one of grains of paradise, galangal and 6-paradol.
[0006] The device may be at least partially combustible.
[0007] The device may include a filter disposed toward an end of the device and coupled to the wrapper.
[0008] The device may include a capsule operable to be broken by finger pressure.
[0009] The first agent may be disposed in the tobacco, and a second agent that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel may be disposed in the capsule.
[0010] The second agent may activate the TRPM8 channel and be operable to provide a cooling sensation.
[0011] The second agent may include at least one of menthol, physcool (monomenthyl succinate), icilin, geraniol, linalool, hydroxycitronellal, WS-3, WS-23, PMD38, Cool-actP, FrescolatMGA, FrescolatMA and PMD38.
[0012] The second agent may activate the TRPV3 channel and be operable to provide a warming sensation.
[0013] The second agent may include at least one of carvacrol, thymol, eugenol, eucalyptol, incensol, borneol, camphor, dihydrocarveol.
[0014] The second agent may activate the TRPV1 channel.
[0015] The second agent may include at least one of Szechuan pepper, all spice, mustard and rosemary.
[0016] The device may include a second agent that activates a TRPM8 channel and is operable to provide a cooling sensation.
[0017] The device may include a second agent that activates a TRPV3 channel and is operable to provide a warming sensation.
[0018] The device may include a second agent that activates the TRPV1 channel.
[0019] The tobacco may be a low nicotine tobacco.
[0020] The device may include at least one of herb and tea leaves.
[0021] In another example, a device includes a wrapper, at least one of herb and tea leaves disposed in the wrapper, and a first agent that activates a TRPA1 channel disposed in the wrapper.
[0022] The first agent may include at least one of grains of paradise, galangal and 6-paradol.
[0023] The device may include a capsule operable to be broken by finger pressure. The first agent may be disposed in the at least one of herb and tea leaves. A
second agent that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel may be disposed in the capsule.
second agent that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel may be disposed in the capsule.
[0024] The second agent may activate the TRPM8 channel and be operable to provide a cooling sensation.
[0025] The second agent may activates the TRPV3 channel and be operable to provide a warming sensation.
[0026] The second agent may activate the TRPV1 channel.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 is a perspective view of an exemplary device for delivering compositions of the present disclosure.
[0028] Figure 2 is an exploded schematic side view of an exemplary embodiment of the device of Figure 1.
[0029] Figure 3 is a schematic side view of an exemplary cellulose acetate tip of the device of Figure 1.
DETAILED DESCRIPTION
DETAILED DESCRIPTION
[0030] Embodiments described herein relate generally to an improved composition to modulate the sensory effects of low nicotine or non-nicotine tobacco or tobacco substitute products and providing relief from acute nicotine craving symptoms.
[0031] Sensory aspects of smoking contribute to smoking behavior and relief of cigarette craving both through conditioned or learned association with nicotine delivery, but also through direct autonomic and sensory-metabolic reflexes independent of nicotine entry into the brain. In particular, tracheal stimulation (sometimes referred to as "throat scratch,"
"throat impact" or "throat hit") is reported as a component of smoking satisfaction and relief of cigarette craving. Isolated reduction of throat sensations with local anesthetics reduce the relief of smoking craving induced by nicotine-containing cigarette smoke;
conversely, maintenance of throat scratch while disabling olfaction and oral taste sensation with an anesthetic mouthwash can alleviate the negative affect associated with cigarette craving.
The "throat scratch" can affect perceived taste qualities and more subtle throat and airway autonomic sensory nerve stimulation, which can have effects beyond taste sensations.
"throat impact" or "throat hit") is reported as a component of smoking satisfaction and relief of cigarette craving. Isolated reduction of throat sensations with local anesthetics reduce the relief of smoking craving induced by nicotine-containing cigarette smoke;
conversely, maintenance of throat scratch while disabling olfaction and oral taste sensation with an anesthetic mouthwash can alleviate the negative affect associated with cigarette craving.
The "throat scratch" can affect perceived taste qualities and more subtle throat and airway autonomic sensory nerve stimulation, which can have effects beyond taste sensations.
[0032] An understanding of actions of nicotine that permit improvements in mimicry of its subjective and physiological effects in a non-combustible simulated cigarette is that its initial perceived actions are upon sensory receptors in the respiratory tract.
Cigarette smoke constituents, including but not limited to nicotine, act on sensory and autonomic afferent nerve terminals sending sensory information to the brain from the mouth, throat and respiratory tract via the vagus, trigeminal and other cranial nerves, and induce autonomic reflexes and effects in the central nervous system that contribute to the subjective experience of cigarette smoking, including "throat scratch," and to relief of craving, and also to subjective reflex-mediated experiences such as "head rush." Cigarette smoking causes EEG
changes and corresponding subjective experiences in the brain via sensory reflexes even before nicotine is absorbed and transported to the brain.
Cigarette smoke constituents, including but not limited to nicotine, act on sensory and autonomic afferent nerve terminals sending sensory information to the brain from the mouth, throat and respiratory tract via the vagus, trigeminal and other cranial nerves, and induce autonomic reflexes and effects in the central nervous system that contribute to the subjective experience of cigarette smoking, including "throat scratch," and to relief of craving, and also to subjective reflex-mediated experiences such as "head rush." Cigarette smoking causes EEG
changes and corresponding subjective experiences in the brain via sensory reflexes even before nicotine is absorbed and transported to the brain.
[0033] The pharmacological actions of nicotine include actions on nicotinic cholinergic receptors in the central and peripheral nervous systems. A class of sensory receptors distinct from cholinergic receptors can be exploited by compositions and devices of this disclosure to provide mimicry of the sensation of inhalation of cigarette smoke to a degree sufficient to provide satisfaction and attenuation of craving for nicotine-containing cigarettes. Simulation of nicotine's actions on sensory receptors on nerve endings in the respiratory tract is achieved with selected volatile agents acting on the chemesthetic sensory modality mediated by transient receptor potential channels, which are pharmacologically distinct from nicotine-responsive cholinergic or acetylcholine receptors.
[0034] The chemical senses comprise taste, olfaction, and "chemesthesis"
(also known as the "common chemical sense," or trigeminal chemosensation). Chemesthesis refers to actions of chemicals, e.g. food constituents, on nerve endings mediating sensations of pain or temperature, including the pungent, hot or cool sensations elicited by specific constituents of many ingested or inhaled substances including hot peppers (capsaicin), black pepper (piperine), menthol, garlic (allicin), horseradish and wasabi (allyl isothiocyanate), camphor, wintergreen, cinnamon (cinnamaldehyde), carbonated beverages (carbon dioxide) and some air pollutants. Such sensations in the oral and nasal cavities are mediated via the trigeminal nerve, and are elements of the somatosensory system, distinguishing them from olfaction and taste, although chemesthesis is an integral component of characteristic sensory information about foods or airborne chemicals.
(also known as the "common chemical sense," or trigeminal chemosensation). Chemesthesis refers to actions of chemicals, e.g. food constituents, on nerve endings mediating sensations of pain or temperature, including the pungent, hot or cool sensations elicited by specific constituents of many ingested or inhaled substances including hot peppers (capsaicin), black pepper (piperine), menthol, garlic (allicin), horseradish and wasabi (allyl isothiocyanate), camphor, wintergreen, cinnamon (cinnamaldehyde), carbonated beverages (carbon dioxide) and some air pollutants. Such sensations in the oral and nasal cavities are mediated via the trigeminal nerve, and are elements of the somatosensory system, distinguishing them from olfaction and taste, although chemesthesis is an integral component of characteristic sensory information about foods or airborne chemicals.
[0035] In the throat, respiratory tract and lungs, chemesthetic signals are transmitted to the brain via the glossopharyngeal and vagus nerves. Chemesthetic signals can thereby directly affect brain activity in the somatosensory cortex and other brain regions, including appetitive circuits involved in craving for particular foods or other chemesthetic stimuli including tobacco smoke.
[0036] Crossover of chemesthetic signaling provided by compounds of the present disclosure with chemesthetic signaling pathways involved in perception and physiological responses to tobacco smoke contributes to the ability of devices and compositions of the present disclosure to reduce craving or negative affect or mood associated with delay or withdrawal of tobacco smoke.
[0037] During tobacco smoking, chemosensory signals from the respiratory tract inform the brain that smoke, likely containing nicotine based on experience, has been inhaled, thereby triggering alterations of activity in appetitive circuits involved in converting absence of central nicotinic receptor activation into negative affect or dysphoria associated with cigarette craving. Activation of chemosensory neurons that anatomically or functionally overlap with neurons terminating in the airways that respond to nicotine and other smoke constituents provides signals to the brain that similarly trigger neural reflex-mediated relief of nicotine-withdrawal dysphoria without actually delivering nicotine or potentially toxic smoke constituents resulting from combustion of tobacco. Similarly, mimicry of tactile, kinesthetic, organoleptic aspects of cigarette smoking, in addition to chemosensory mimicry, reinforces the ability of devices and compositions of the present disclosure to relieve symptoms of nicotine withdrawal or cigarette craving.
[0038] Transient receptor potential ion channels ("TRP channels" or, simply "TRP") are a class of receptors on sensory nerves that trigger chemesthetic nerve activation. TRP
channels mediate pungent, hot or cool sensations of food or air. TRP
activation on sensory nerve endings can induce local effects in addition to sensation per se (e.g.
focal vasodilatation via axon reflex) or may trigger sensory-autonomic reflexes (e.g changes in bronchial tone, coughing, sneezing or changes in body temperature regulation, or subjective sensations) mediated through the reflex arcs involving the spinal cord or brain. While TRP
activation can provide warning of potentially noxious environmental or dietary factors, TRP
stimulation can also elicit pleasure or satisfaction, as is implied by the examples of common TRP activators above. A feature of TRP activation is that chemesthetic sensations (or TRP
sensations), which are generally more sensitive to temperature sensations than to smell sensations provide less inherent discrimination between different agonists than is the case for olfactory sensation. Sensory nerve endings associated with the trigeminal, glossopharyngeal and vagus nerves may contain multiple types of chemosensory receptors, providing a basis for chemesthetic mimicry by chemically diverse agents.
channels mediate pungent, hot or cool sensations of food or air. TRP
activation on sensory nerve endings can induce local effects in addition to sensation per se (e.g.
focal vasodilatation via axon reflex) or may trigger sensory-autonomic reflexes (e.g changes in bronchial tone, coughing, sneezing or changes in body temperature regulation, or subjective sensations) mediated through the reflex arcs involving the spinal cord or brain. While TRP
activation can provide warning of potentially noxious environmental or dietary factors, TRP
stimulation can also elicit pleasure or satisfaction, as is implied by the examples of common TRP activators above. A feature of TRP activation is that chemesthetic sensations (or TRP
sensations), which are generally more sensitive to temperature sensations than to smell sensations provide less inherent discrimination between different agonists than is the case for olfactory sensation. Sensory nerve endings associated with the trigeminal, glossopharyngeal and vagus nerves may contain multiple types of chemosensory receptors, providing a basis for chemesthetic mimicry by chemically diverse agents.
[0039] TRP channels can be activated by concentrations of compounds below those that cause actual physical changes in the respiratory tract, acting as sensitive sentinels of possible irritation or damage. TRP channel activators therefore provide a potential mode of action for volatile constituents to have smoke-mimetic chemosensory or chemesthetic effects without delivery of otherwise bioactive quantities of the sensory agents into the body.
[0040] Referring to Fig. 1, in some embodiments, an exemplary cigarette device 10 may be approximately the size and shape of a conventional cigarette. Volatile constituents are dispersed within a matrix 12 encased within a wrapper 14 resembling the outer wrap of a conventional cigarette. In some embodiments, the wrapper is relatively nonporous, liquid impermeable wrapper 14. The matrix 12 may be provided by a porous material such as cellulose or it may also be provided by tobacco or tobacco substitute product.
The end 16 of the device 10 may be constructed to resemble a conventional filter rod in appearance and/or feel. In some embodiments, a filter rod is used at the end 16 of the device 10. The present disclosure is not restricted to cigarette-like devices, but also includes substitute cigars, pipes, e-cigarettes, inhalers, and other devices used to smoke tobacco or mimic smoking.
The end 16 of the device 10 may be constructed to resemble a conventional filter rod in appearance and/or feel. In some embodiments, a filter rod is used at the end 16 of the device 10. The present disclosure is not restricted to cigarette-like devices, but also includes substitute cigars, pipes, e-cigarettes, inhalers, and other devices used to smoke tobacco or mimic smoking.
[0041] Referring to Fig. 2, an exemplary embodiment of a device 10 includes a substrate 122 enclosed in a wrapper 123 resembling the outer wrap of a cigarette. The substrate 122 may include a channel 124. The channel 124 may include a tobacco or substitute tobacco product 126 and a porous substrate 128 to contain constituents described herein. The substrate 128 may also be omitted and the constituents applied directly to the tobacco or tobacco substitute product. The tobacco or substitute tobacco product 126 may be separated from the substrate 128 by a substantially non-porous or liquid impermeable barrier to provide separation between the tobacco or substitute tobacco product and the constituents of the disclosure. This may protect the constituents from the heat of burning the tobacco or substitute tobacco product.
[0042] An untreated region 130 may be included at a second end 132 of the device 10, which is subjected to mouth-applied suction by a user. The untreated region 130 may be untreated cellulose or other filtering material. In some embodiments, the untreated region 130 may be a filter plug. In some embodiments, the untreated region 130 may be a cellulose acetate tip with a micro capsule (discussed in more detail with respect to Fig. 3).
[0043] The region 130 and part of the channel 124 may be covered with a wrap 134.
The wrap 134 enhances visual similarity between the device 10 and a cigarette.
In some cases, the substrate 128 may be disposed inside the region of the device 10 covered by the wrap 134. A portion 136 of the wrap 134 may include trade dress for identifying the device or the maker thereof.
The wrap 134 enhances visual similarity between the device 10 and a cigarette.
In some cases, the substrate 128 may be disposed inside the region of the device 10 covered by the wrap 134. A portion 136 of the wrap 134 may include trade dress for identifying the device or the maker thereof.
[0044] In an embodiment, the device 10 may have a length of approximately 100 mm and a diameter of approximately 7.9 mm in diameter. The channel 124 may be approximately 80 mm in length and the region 130 may be approximately 20 mm in length.
The substrate 128 may be 10 mm or more in length. The wrap 134 may be approximately 30 mm in length.
The substrate 128 may be 10 mm or more in length. The wrap 134 may be approximately 30 mm in length.
[0045] Referring to Fig. 3, the region 130a is an exemplary cellulose acetate tip with a pellet or capsule 140, such as a micro bead, that is stable and does not release the active agents therein until crushed or broken by finger pressure. The micro capsule 140 may be of various sizes such as 3.5-5mm in diameter. The micro capsule 140 may be arranged with its center at approximately 15 mm from the second end 132.
[0046] The present disclosure provides a selection of volatile activators of TRP channels and acid sensitive ion channels which, when incorporated into a low nicotine or non-nicotine combustion or heating device, provide improved chemosensory mimicry of the experience of nicotine delivery versus prior low nicotine or non-nicotine delivery devices.
Importantly, the compositions of this disclosure may impart chemosensory activity without also providing undesirable flavors.
Importantly, the compositions of this disclosure may impart chemosensory activity without also providing undesirable flavors.
[0047] Compositions of the disclosure include ingredients that are co-delivered with tobacco or botanical tobacco substitute smoke, or with vapor from tobacco or botanical tobacco substitute materials. There are two primary methods described in this disclosure: 1) incorporation of sensory agents in the tobacco or tobacco substitutes prior to forming them into cigarettes or heat-not-burn products ; or 2) inclusion of sensory agents into the filter of a cigarette such that they are released into the mainstream smoke during inhalation. In this latter embodiment, filter elements are optionally pellets or capsules that are stable and do not release the active agents until crushed or broken by finger pressure, or by incorporating segmented filter technology to embed a section to co-deliver ingredients.
[0048] Agents of the disclosure for simulating or amplifying throat or airway sensations associated with cigarette and herbal smoking or aerosolizing include sensate constituents of aframomum malagueta, including 6-paradol, of galangal root, including galangal acetate and its analogs, of hydroxy-alpha sanshool which is found in extracts of Szechuan peppers, of thymol which is found in extracts of Thyme, and of camphor and its analogs which is found in extracts of rosemary.
[0049] In one embodiment, a sensory agent, which optionally comprises pulverized aframomum melegueta seeds, ethanolic or methanolic extracts of the seeds, or purified, semi-purified or synthetic compounds found in the seeds, including 6-paradol, are applied to, or mixed with, tobacco or botanical tobacco substitute. The treated tobacco or tobacco substitute is then formed into a cigarette by standard manufacturing methods.
Similarly, powdered galangal root, or ethanolic galangal extracts or purified or semi-purified chemical constituents are applied to tobacco or tobacco substitute and formed into cigarettes.
Similarly, powdered galangal root, or ethanolic galangal extracts or purified or semi-purified chemical constituents are applied to tobacco or tobacco substitute and formed into cigarettes.
[0050] In one embodiment, 6-paradol or galangal is combined in a cigarette, which may include the tobacco or botanical tobacco substitute, with an agent that provides a cooling effect by acting on TRPM8, a transient receptor potential channel mediating a cooling sensation evoked by agonists, including but not limited to menthol, physcool (monomenthyl succinate), icilin, geraniol, linalool, hydroxycitronellal, WS-3, WS-23, PMD38, Cool-actP, FrescolatMGA, FrescolatMA and PMD38. The cooling agent is optionally added to the tobacco and is delivered by combustion or volatilization in a heat-not-burn device. In another embodiment the cooling agent is incorporated into the cigarette filter, either by application to the filter itself, or by encapsulation in a crushable pellet or capsule that releases volatile cooling agent into mainstream smoke when broken by finger pressure.
[0051] In one embodiment, 6-paradol or galangal is combined in a cigarette, which may include the tobacco or botanical tobacco substitute, with agents that provide an additional trigeminal sensory effect by acting on TRPA1 and TRPV1, transient receptor potential channels evoked by agonists, including but not limited to hydroxy-alpha sanshool which is found in extracts of Szechuan peppers, isothiocyanates which are found in extracts of Mustard Seed, Yellow Mustard, or combinations thereof. The TRPV1 and TRPA1 agonists are optionally incorporated into the tobacco, as either a purified or semi-purified compound, a semi-purified extract, or as a simple ethanolic or methanolic extract of a botanical material of which the TRPV1 and TRPA1 agent is an endogenous constituent.
[0052] In one embodiment, 6-paradol or galangal is combined in a cigarette, which may include the tobacco or botanical tobacco substitute, with an agent that provides an additional trigeminal sensory effect by acting on TRPV3, a transient receptor potential channel mediating a warming sensation evoked by agonists, including but not limited to carvacrol, thymol, eugenol, eucalyptol, incensol, borneol, camphor, dihydrocarveol or combinations thereof. The TRPV3 agonist is optionally incorporated into the tobacco or herbal cut rag, as either a purified or semi-purified compound, a semi-purified extract, or as a simple ethanolic extract of a botanical material of which the TRPV3 agent is an endogenous constituent.
[0053] In another embodiment, the TRPV1 and/or TRPV3 agents are incorporated into the cigarette filter, either by application to the filter itself, or by encapsulation in a crushable pellet or capsule that releases volatile cooling agent into mainstream smoke when broken by finger pressure. Many TRPV1 and/or TRPV3 agents, such as terpenoid compounds are volatile and therefore advantageous for delivery in the filter, entering mainstream smoke during its passage through the filter. Examples of TRPV1 agents that may be included in the filter and/or capsule include Szechuan pepper, all spice, mustard and rosemary. Examples of TRPV3 agents that may be included in the filter and/or capsule include camphor, carvacrol, thymol, and incensole acetate.
[0054] In one embodiment, a cooling agent and a TRPV3 activating agent are combined in a pellet or capsule in the filter of a cigarette, while a TRPA1 agonist, including but not limited to aframomum malagueta extract (or 6-paradol) or a galangal extract or galangal acetate) is incorporated into tobacco and released into mainstream smoke during combustion.
[0055] In one embodiment, a cooling agent and a TRPV1 activating agent are combined in a pellet or capsule in the filter of a cigarette, while a TRPA1 agonist, including but not limited to aframomum malagueta extract (or 6-paradol) or a galangal extract or galangal acetate) is incorporated into tobacco and released into mainstream smoke during combustion.
[0056] TRPV3 and TRPA1 activating agents may be more expensive and more volatile than TRPV1 activating agents. Therefore, inclusion of the TRPV3 and TRPA1 agents in a pellet or capsule offers advantages in using less of the agent (more cost effective) and improving the shelf life of the product.
[0057] Example 1
[0058] Aframomum melegueta seeds (200 grams), and powdered galangal root, or ethanolic galangal extracts, were pulverized in a coffee grinder and extracted through a heated extraction process with ethanol for 3 hours. The extract was filtered in three separate steps. Using a syringe and needle, 0.1 ml was injected into a light cigarette, withdrawing the needle while dispensing the extract from the syringe down the length of the tobacco column.
After being allowed to dry, the cigarette displayed an intensified throat sensation, mimicking a key element of the sensory impact of a stronger cigarette.
After being allowed to dry, the cigarette displayed an intensified throat sensation, mimicking a key element of the sensory impact of a stronger cigarette.
[0059] Example 2
[0060] Aframomum melegueta seeds (2.4 kg), thyme leaves (7.4 kg), rosemary (6.6 kg), and powdered galangal root (8.1 kg), were pulverized in a coffee grinder and extracted through a heated extraction process with 106 liters of methanol for 3 hours.
The extract was filtered in three separate steps. This extract was applied to tea leaves as a tobacco substitute.
Application was by fine spray over the non-tobacco herbal cut-rag which was then mixed and tumbled to coat evenly. The treated cut-rag was dried in a commercial grade oven for 4 hours. Following the drying process, the cut-rag was sprayed with propylene glycol to reach a moisture level of approximately 18%. The non-tobacco herbal cut-rag was manufactured into cigarettes on a Hauni Protos high speed cigarette making line. The cigarettes displayed an intensified throat sensation, mimicking a key element of the sensory impact of a nicotine containing tobacco cigarette.
The extract was filtered in three separate steps. This extract was applied to tea leaves as a tobacco substitute.
Application was by fine spray over the non-tobacco herbal cut-rag which was then mixed and tumbled to coat evenly. The treated cut-rag was dried in a commercial grade oven for 4 hours. Following the drying process, the cut-rag was sprayed with propylene glycol to reach a moisture level of approximately 18%. The non-tobacco herbal cut-rag was manufactured into cigarettes on a Hauni Protos high speed cigarette making line. The cigarettes displayed an intensified throat sensation, mimicking a key element of the sensory impact of a nicotine containing tobacco cigarette.
[0061] Example 3
[0062] Aframomum melegueta seeds (200 grams), and powdered galangal root, or ethanolic galangal extracts, were pulverized in a coffee grinder and extracted through a heated extraction process with methanol for 3 hours. The extract was filtered in three separate steps. This extract was applied to a very low nicotine (VLN) tobacco cut-rag with less than 0.04% nicotine. Application was by fine spray over the cut-rag which was then mixed and tumbled to coat evenly. The treated cut-rag was dried in a commercial grade oven for 4 hours. Following the drying process, the cut-rag was sprayed with propylene glycol to reach a moisture level of approximately 18%. The VLN cut-rag was hand-rolled into cigarettes, which displayed an intensified throat sensation, mimicking a key element of the sensory impact of a tobacco cigarette with regular level of nicotine content.
[0063] Example 4
[0064] Aframomum melegueta seeds (200 grams), and powdered galangal root, or ethanolic galangal extracts, were pulverized in a coffee grinder and extracted through a heated extraction process with methanol for 3 hours. The extract was filtered in three separate steps. This extract was applied to a blend of herb and tea leaves as a tobacco substitute. Application was by fine spray over the cut-rag which was then mixed and tumbled to coat evenly. The treated cut-rag was dried in a commercial grade oven.
Following the drying process, the cut-rag was cut and ground finely and sprayed with vegetable glycerin to reach a moisture level of approximately 18%. The moist cut-rag was then placed into a herbal vaporizer device, which upon heating displayed an intensified throat sensation, mimicking a key element of the sensory impact of a tobacco vaporizer. The composition of Example 4 is particularly advantageous for use in non-combustion heat not burn technology in which the composition is heated to release vapor or aerosol but burning and combustion is not required. The device may be a heat stick, for example a shorter cigarette type device including a tobacco blend. The device may also be a reusable device that accepts any type of cut rag or material in a heating chamber.
Following the drying process, the cut-rag was cut and ground finely and sprayed with vegetable glycerin to reach a moisture level of approximately 18%. The moist cut-rag was then placed into a herbal vaporizer device, which upon heating displayed an intensified throat sensation, mimicking a key element of the sensory impact of a tobacco vaporizer. The composition of Example 4 is particularly advantageous for use in non-combustion heat not burn technology in which the composition is heated to release vapor or aerosol but burning and combustion is not required. The device may be a heat stick, for example a shorter cigarette type device including a tobacco blend. The device may also be a reusable device that accepts any type of cut rag or material in a heating chamber.
[0065] It will be appreciated that the described exemplary constituents are not limiting and the described constituents include equivalents such as synthetic alternatives. It will also be appreciated that description of constituents in compositions as by weight or by volume is merely exemplary and is not limiting. Constituents may be measured using any of a variety of available methods.
[0066] In addition, it will be appreciated that the above described devices and compositions are not limited to cigarette-like rods, but are also applicable to other devices such as inhalers that may be used to deliver the constituent(s). Also, it will be appreciated that the above described devices are applicable to applications beyond smoking substitution and smoking cessation.
[0067] While various embodiments in accordance with the disclosed principles have been described above, it should be understood that they have been presented by way of example only, and are not limiting. Thus, the breadth and scope of the invention(s) should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the claims and their equivalents issuing from this disclosure.
Furthermore, the above advantages and features are provided in described embodiments, but shall not limit the application of such issued claims to processes and structures accomplishing any or all of the above advantages.
Furthermore, the above advantages and features are provided in described embodiments, but shall not limit the application of such issued claims to processes and structures accomplishing any or all of the above advantages.
Claims (28)
1. A device, comprising:
a wrapper;
tobacco disposed in the wrapper; and a first agent that activates a TRPA1 channel disposed in the wrapper.
a wrapper;
tobacco disposed in the wrapper; and a first agent that activates a TRPA1 channel disposed in the wrapper.
2. The device of claim 1, wherein the first agent includes at least one of grains of paradise, galangal and 6-paradol.
3. The device of claim 1, wherein the device is at least partially combustible.
4. The device of claim 1, further comprising a filter disposed toward an end of the device and coupled to the wrapper.
5. The device of claim 4, further comprising a capsule operable to be broken by finger pressure.
6. The device of claim 5, wherein the first agent is disposed in the tobacco, and a second agent that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel is disposed in the capsule.
7. The device of claim 6, wherein the second agent activates the TRPM8 channel and is operable to provide a cooling sensation.
8. The device of claim 7, wherein the second agent includes at least one of menthol, physcool (monomenthyl succinate), icilin, geraniol, linalool, hydroxycitronellal, WS-3, WS-23, PMD38, Cool-actP, FrescolatMGA, FrescolatMA and PMD38.
9. The device of claim 6, wherein the second agent activates the TRPV3 channel and is operable to provide a warming sensation.
10. The device of claim 9, wherein the second agent includes at least one of carvacrol, thymol, eugenol, eucalyptol, incensol, borneol, camphor, dihydrocarveol.
11. The device of claim 6, wherein the second agent activates the TRPV1 channel.
12. The device of claim 11, wherein the second agent includes at least one of Szechuan pepper, all spice, mustard and rosemary.
13. The device of claim 1, further comprising a second agent that activates a channel and is operable to provide a cooling sensation.
14. The device of claim 1, further comprising a second agent that activates a channel and is operable to provide a warming sensation.
15. The device of claim 1, further comprising a second agent that activates the TRPV1 channel.
16. The device of claim 1, wherein the tobacco is a low nicotine tobacco.
17. The device of claim 16, further comprising at least one of herb and tea leaves.
18. A device, comprising:
a wrapper;
at least one of herb and tea leaves disposed in the wrapper; and a first agent that activates a TRPA1 channel disposed in the wrapper.
a wrapper;
at least one of herb and tea leaves disposed in the wrapper; and a first agent that activates a TRPA1 channel disposed in the wrapper.
19. The device of claim 18, wherein the first agent includes at least one of grains of paradise, galangal and 6-paradol.
20. The device of claim 18, further comprising a capsule operable to be broken by finger pressure, wherein the first agent is disposed in the at least one of herb and tea leaves, and a second agent that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel is disposed in the capsule.
21. The device of claim 20, wherein the second agent activates the TRPM8 channel and is operable to provide a cooling sensation.
22. The device of claim 20, wherein the second agent activates the TRPV3 channel and is operable to provide a warming sensation.
23. The device of claim 20, wherein the second agent activates the TRPV1 channel.
24. A composition, comprising:
at least one of tobacco, herb and tea leaves;
a first agent that activates a TRPA1 channel intermixed with the at least one of tobacco, herb and tea leaves; and a second agent, distinct from the first agent, that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel, wherein the composition releases volatile compounds when heated at a temperature below a burning point of the composition.
at least one of tobacco, herb and tea leaves;
a first agent that activates a TRPA1 channel intermixed with the at least one of tobacco, herb and tea leaves; and a second agent, distinct from the first agent, that activates at least one of a TRPM8 channel, a TRPV3 channel, and a TRPV1 channel, wherein the composition releases volatile compounds when heated at a temperature below a burning point of the composition.
25. The composition of claim 24, wherein the first agent includes at least one of grains of paradise, galangal and 6-paradol.
26. The device of claim 24, wherein the second agent activates the TRPM8 channel and is operable to provide a cooling sensation.
27. The device of claim 24, wherein the second agent activates the TRPV3 channel and is operable to provide a warming sensation.
28. The device of claim 24, wherein the second agent activates the TRPV1 channel.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662398875P | 2016-09-23 | 2016-09-23 | |
US62/398,875 | 2016-09-23 | ||
PCT/US2017/053052 WO2018057954A1 (en) | 2016-09-23 | 2017-09-22 | Agents and methods for modulating the sensory impact of tobacco or herbal smoke |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3037723A1 true CA3037723A1 (en) | 2018-03-29 |
Family
ID=61687788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3037723A Pending CA3037723A1 (en) | 2016-09-23 | 2017-09-22 | Agents and methods for modulating the sensory impact of tobacco or herbal smoke |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180084827A1 (en) |
EP (1) | EP3515215A4 (en) |
CN (1) | CN109922676A (en) |
CA (1) | CA3037723A1 (en) |
WO (1) | WO2018057954A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108936783B (en) * | 2018-09-17 | 2021-07-02 | 中烟施伟策(云南)再造烟叶有限公司 | Method for preparing smoking material for cigarette by heating and non-burning through granulation by boiling method |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1284151A (en) | 1969-08-18 | 1972-08-02 | Int Flavors & Fragrances Inc | Tobacco containing encapsulated flavor |
US5383478A (en) * | 1993-01-12 | 1995-01-24 | Duke University | Low tar and low nicotine cigarette adapted to provide enhanced smoking satisfaction |
US10285431B2 (en) * | 2004-12-30 | 2019-05-14 | Philip Morris Usa Inc. | Encapsulated flavorant designed for thermal release and cigarette bearing the same |
US7578298B2 (en) * | 2005-02-04 | 2009-08-25 | Philip Morris Usa Inc. | Flavor capsule for enhanced flavor delivery in cigarettes |
CN101116534A (en) * | 2007-09-14 | 2008-02-06 | 谢兰银 | Health type solid cigarette bar capable of replacing smokables |
CN101263932A (en) * | 2008-04-30 | 2008-09-17 | 钱兆林 | Green cigarette-tea tobacco |
US20110104080A1 (en) * | 2009-11-03 | 2011-05-05 | David Salloum Salloum | Oral Compositions for Treatment of Dry Mouth |
EP3295794A1 (en) | 2010-07-27 | 2018-03-21 | Flex Pharma, Inc. | Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise |
US8646461B2 (en) * | 2011-12-14 | 2014-02-11 | Sentiens, Llc | Device and method for simulating chemosensation of smoking |
US10335378B2 (en) | 2013-03-15 | 2019-07-02 | Altria Client Services Llc | Inhibition of central nervous system effects from smoking and sensory effects from smoking |
SG10201800938PA (en) * | 2013-08-02 | 2018-03-28 | Sentiens Llc | Compositions and their use for smoking cessation and other treatments |
LU92296B1 (en) * | 2013-10-18 | 2015-04-20 | Valeo Lab Gmbh | Liquid composition for an electronic cigarette |
UA118772C2 (en) * | 2013-12-20 | 2019-03-11 | Філіп Морріс Продактс С.А. | Smoking article having a filter including a capsule |
WO2015153184A1 (en) * | 2014-04-01 | 2015-10-08 | The Procter & Gamble Company | Method for screening trp channels |
CN104770858A (en) * | 2015-02-11 | 2015-07-15 | 贵州中烟工业有限责任公司 | Gastric mucosa protected mouth-holding type smokeless tobacco product and preparing method thereof |
-
2017
- 2017-09-22 CA CA3037723A patent/CA3037723A1/en active Pending
- 2017-09-22 EP EP17854026.6A patent/EP3515215A4/en active Pending
- 2017-09-22 US US15/713,353 patent/US20180084827A1/en not_active Abandoned
- 2017-09-22 CN CN201780068739.8A patent/CN109922676A/en active Pending
- 2017-09-22 WO PCT/US2017/053052 patent/WO2018057954A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018057954A1 (en) | 2018-03-29 |
CN109922676A (en) | 2019-06-21 |
US20180084827A1 (en) | 2018-03-29 |
EP3515215A1 (en) | 2019-07-31 |
EP3515215A4 (en) | 2020-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10098379B2 (en) | Device and method for simulating chemosensation of smoking | |
EP3136895B1 (en) | Flavoured nicotine powder inhaler | |
WO2015078070A1 (en) | Electronic cigarette liquid solvent and electronic cigarette liquid | |
EP2941135A1 (en) | Tobacco substitute | |
WO2020089071A1 (en) | Smoking substitute consumable | |
WO2020089055A1 (en) | Smoking substitute consumable | |
US20180084827A1 (en) | Agents and methods for modulating the sensory impact of tobacco or herbal smoke | |
EP3873261A1 (en) | Smoking substitute consumable | |
EP3873253A1 (en) | Smoking substitute consumable | |
EP3873258B1 (en) | Smoking substitute consumable | |
KR20230051697A (en) | Aerosol Generating Material with Burn Retardant Properties and Uses Thereof | |
KR20230051695A (en) | Burn Retardant Materials and Their Uses | |
WO2020089068A1 (en) | Smoking substitute consumable | |
US20220022521A1 (en) | New tobacco substitutes | |
EP3873259B1 (en) | Smoking substitute consumable | |
WO2024161121A1 (en) | An aerosol generating material | |
TW202432008A (en) | An aerosol generating material | |
WO2024161117A1 (en) | An aerosol generating material | |
TW202432009A (en) | An aerosol generating material | |
CN116035251A (en) | Packaging material with flame retardant properties and use thereof | |
WO2020089050A1 (en) | Smoking substitute consumable | |
TW202027623A (en) | Smoking substitute consumable |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220915 |
|
EEER | Examination request |
Effective date: 20220915 |
|
EEER | Examination request |
Effective date: 20220915 |
|
EEER | Examination request |
Effective date: 20220915 |
|
EEER | Examination request |
Effective date: 20220915 |
|
EEER | Examination request |
Effective date: 20220915 |
|
EEER | Examination request |
Effective date: 20220915 |
|
EEER | Examination request |
Effective date: 20220915 |